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Abstract
Inflammatory mechanisms are activated, and thrombotic complications occur during the initial
months after coronary artery bypass grafting (CABG). Therefore, changes over time of platelet
activation andplatelet–leukocyte interactions after CABGare of interest.Whole-blood flow cytometry
was performed before, and 4–6 days, one month, and three months after elective CABG in 54 men
with stable coronary artery disease treated with acetylsalicylic acid (ASA). Single platelets and
platelet–leukocyte aggregates (PLAs) among monocytes (P-Mon), neutrophils (P-Neu), and lympho-
cytes (P-Lym) were studied without and with stimulation by submaximal concentrations of ADP,
thrombin, and the thromboxane analog U46619. White blood cell counts were increased during the
initial postoperative course, and platelet counts were increased after one month. Platelet P-selectin
expression was significantly enhanced at onemonth when stimulated by thrombin and U46619 and
at three months with ADP and thrombin. All PLAs subtypes were increased at one month without
stimulation in vitro. P-Mon and P-Neu stimulated by ADP, thrombin, or U46619 were significantly
increased one month after the operation but decreased compared to baseline at three months.
Agonist stimulated P-Lyms were increased at one month and remained increased at three months
after ADP stimulation. There was significant platelet activation and formation of PLAs unstimulated
and after agonist stimulation by ADP, thrombin, and a thromboxane analog after CABG in patients
with stable coronary artery disease irrespective of ASA treatment. Changes observed up to three
months after CABG support further studies of the clinical implications of protracted increases in
platelet activation and platelet–leukocyte interactions.
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Introduction
During recent years, it has become increasingly clear that
platelets and platelet–leukocyte interactions are involved in
the complex pathophysiology of atherosclerosis and the termi-
nology athero-thrombosis is frequently used in this context [1–
8]. Cardiopulmonary bypass activates inflammatory mechan-
isms and several aspects of hemostasis [9,10]. We have pre-
viously reported on biphasic pro-thrombotic and inflammatory
responses after coronary artery bypass grafting (CABG) in a
study focusing on the first week after surgery [11]. Thrombo-
embolic events may occur during the first month after cardiac
surgery and early vein graft failure is related to thrombosis and
high platelet reactivity [12,13]. Thus, more intense antiplatelet
therapy than acetylsalicylic acid (ASA) alone may be required
to improve the prognosis of patients with stable coronary artery
disease undergoing CABG [14,15].
We have previously reported on the efficacy of different ASA
dosages following CABG and found that 75 mg twice daily or
160 mg once daily inhibited thromboxane-dependent platelet acti-
vation more effectively than 75 mg once daily [16]. The present
study describes platelet reactivity and circulating platelet–leuko-
cyte aggregates (PLAs) irrespective of ASA dosage following
elective CABG in patients without indication for dual antiplatelet
therapy. Flow cytometry of single platelets or PLAs is insensitive
to ASA treatment as such measurements are performed under
static conditions that do not promote thromboxane generation
[17–19]. The present aim was to investigate changes in thrombox-
ane independent platelet activation and platelet–leukocyte inter-
action including responses to agonist stimulation during the
recovery phase, at one and three months after elective CABG in
patients with stable coronary artery disease.
Patients and Methods
Subjects
We included patients with stable angina pectoris scheduled to
undergo elective CABG. Exlusion criteria were intake of any
other platelet inhibitor than ASA during the last seven days
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prior to surgery, known bleeding disorder or kidney failure, pre-
operative platelet count outside of the range 100,000–450,000/µL,
or a hemoglobin level below 8 g/L. We screened 75 subjects of
whom 54 were included in the final analysis; 20 patients were
excluded because of incomplete follow-up with blood samples
and one patient with insulin-treated diabetes mellitus and
advanced three-vessel disease died suddenly two months after
the operation. Results in 42 of the patients have been previously
reported regarding the serum thromboxane B2 effect of the ASA
doses 75 mg twice daily, 160 mg once daily, and 75 mg once
daily [16]. Twelve patients with complete cytometric data and
included in the present analyses were excluded in the previous
study due to faulty compliance with the prescribed ASA dosage
and study procedures.
All patients were treated with ASA (Trombyl®, Pfizer Health
AB, Strängnäs, Sweden) 75 mg OD before the operation and they
received ASA 75 mg OD or BID or 160 mg OD at discharge from
the hospital. The study was approved by the Regional Ethical
Review Board in Stockholm (2011/1074–31/1) and by the
Swedish Medical Products Agency (EudraCT 2011–002233-19).
The study is registered with ClinicalTrials.gov (NCT02482857).
A signed consent form was obtained from all participants.
Study Design
All operations were performed through a standard sternotomy
with the aid of standard cardiopulmonary bypass using a non-
pulsatile centrifugal pump and a membrane oxygenator. The
extracorporeal system was primed with Ringer’s acetate. Cold
blood cardioplegia was used for myocardial protection at a core
temperature of 36°C while the aorta was cross-clamped. Heparin
was given before cardiopulmonary bypass (3 mg/kg) to maintain
activated clotting time >480 s.
Blood Collection
Blood samples were collected for platelet function testing on
admittance before the operation, repeated 4–6 days after surgery
before hospital discharge, and at follow-up after one and three to
four months. Blood was obtained from an antecubital vein using
vacutainer tubes containing EDTA for hematological analyses and
sodium citrate for flow cytometry. Complete blood cell counts
and mean platelet volume were assessed in samples anticoagu-
lated with EDTA, within 20 min of sampling to minimize platelet
swelling, using a MICROS 60 cell counter (ABX Diagnostics,
Montpellier, France).
Flow Cytometric Analyses
Venous blood was collected by venipuncture without stasis, using
siliconized vacutainer tubes containing 1/10 volume of 3.8%
trisodium citrate (Becton Dickinson, Meylan, France).
Five µL aliquots of blood were added to 45 µL HEPES-
buffered saline (150 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l
MgSO4, 10 mmol/l HEPES, pH 7.4) containing appropriately
diluted antibodies as well as agonists or vehicle within 5 min of
collection. Samples were incubated at room temperature and
static conditions in the dark for 20 min, and then diluted and
mildly fixed with 0.5% formaldehyde saline. Agonists (final con-
centrations) used to activate platelets and stimulate PLA forma-
tion in vitro were as follows: 1 µM adenosine diphosphate (ADP),
0.04 U/mL human alpha-thrombin, or 0.3 µM of the thromboxane
analog U46619. We chose these submaximal agonist concentra-
tions based on our previous experience to be able to detect
bidirectional changes in platelet sensitivity to agonist stimulation,
and to employ several agonists to elucidate possible effects via
different activation pathways.
Whole blood flow cytometricmeasurements of platelet P-selectin
expression and PLAs have been described previously [20,21].
Platelets were gated by size and light scatter and verified as
CD42b positive in ≥99% of events. Total leukocytes were gated as
CD45 positive cells using a PE-labeled anti-CD45 MAb (clone J33;
Immunotech, Marseille, France) and neutrophils and lymphocytes
were determined by size and granularity. Monocytes were further
identified using a PC-5 labeled MAb against CD14 (clone RMO52;
Beckman Coulter, Miami, FL, USA).
Platelet P-selectin expression data are reported as percentages
of P-selectin positive cells in the platelet population. PLAs are
presented as percentages of platelet-conjugated leukocytes among
leukocyte subtypes, that is, monocytes (P-Mon), neutrophils (P-
Neu), and lymphocytes (P-Lym).
Statistics
Descriptive statistics with arithmetic means with standard devia-
tions (SD) or 95% confidence intervals (CI) and graphical meth-
ods were used to characterize the data. In cases of skewed
distributions medians with interquartile ranges (IQR) are pre-
sented. A paired t test or in case of skewed distributions the
Wilcoxon test were used to analyze changes from baseline to
postoperative time points. Repeated measures analysis of variance
and the non-parametric Kruskal–Wallis one-way analysis of var-
iance were applied to compare multiple measurements. Spearman
rank order correlations were used to examine P-selectin expres-
sion in relation to PLAs. Two-tailed p-values ≤5% were consid-
ered statistically significant. STATSTICA 13 (StatSoft, Dell) was
used to analyze data.
Results
Preoperative characteristics of the 54 patients are shown in
Table 1. The European System for Cardiac Operative Risk
Evaluation (EuroSCORE) II was used to estimate the risk of
surgery [22]. All patients received an internal mammary graft,
Table I. Characteristics of the 54 patients at recruitment.
Median IQR
Age (years) 68 59–72
Logistic EuroSCORE II %* 1.9 0.5–12.1
Mean SD
BMI (kg/m2) 27 3
Blood pressure (mm Hg)
Systolic 138 19
Diastolic 80 8
Hemoglobin (g/L) 142 10
eGFR (mL/min) 90 28
n %
Male sex 54 100
History of smoking 34 59
Hypertension 43 80
Hyperlipidemia 54 100
Diabetes mellitus 14 26
Medication
Beta blocker 46 85
ACE inhibitor 27 50
Statin 49 91
SD: standard deviation; IQS = interquartile range; ACE: angiotensin-
converting enzyme; eGFR: estimated glomerular filtration rate using
the Cockroft and Gault equation [35].
*Mortality risk according to European System for Cardiac Operative Risk
Evaluation Score II [22].
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and both mammary arteries were used in 19 patients. Mean
cardiopulmonary bypass time was 91 min, and an average of 2.9
grafts was inserted. Median blood loss was 580 (interquartile
range 450–750) ml. Eight of the 54 included patients (15%)
reported minor bleedings such as slight nose bleeds, mouth bleed-
ing associated with tooth brushing, or bruises at the clinical
follow-up after three months. There were no major bleeds or
gastrointestinal complications. None of the patients reported
recurrent angina during the three months of follow-up.
Hematological Analyses
There was a marked drop in average postoperative hemoglobin
level that was normalized at three months after the operation
(Figure 1a). White blood cell counts were increased during the
initial postoperative course, and platelet counts were slightly
reduced after the operation but significantly elevated by 32%
after one month without significant changes of mean platelet
volumes (Figure 1b-d).
Flow Cytometric Data
The patients were treated with different low dosages of ASA after
the operation [16]. Flow cytometric results did not differ between
the three treatment groups, and data could thus be pooled for all
patients (Supplementary Tables I and II).
Platelet Activation
Single platelet surface P-selectin expression was significantly
enhanced at one month when stimulated by thrombin and the
thromboxane analog U46619 (by 8% and 23%, respectively),
and at three months when stimulated by ADP and thrombin (by
10% and 8%, respectively) (Figure 2). Mean levels without ago-
nist stimulation were reduced by 12% from preoperative levels at
three months (from 2.5 ± 1.1% to 2.2 ± 1.1%).
Platelet–Leukocyte Aggregation
The percentages of PLAs separated into subsets are shown in
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Figure 1. Mean levels with 95% confidence limits of (a) hemoglobin, (b) white blood cell counts, (c) platelet counts, and (d) platelet volumes in 54
patients before and after CABG. Dashed columns indicate results 4–6 days after surgery, shaded columns at one months and black columns at three
months. ***p < 0.001 for difference between postoperative and preoperative levels are indicated.
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reflect circulating PLAs when using our methodology [20].
Agonist stimulation increased P-Mon and P-Neu to more than
50% but to less than 10% for P-Lym. In unstimulated samples,
all subsets of PLAs were increased one month after CABG.
The percentages of CD14 positive P-Mons and P-Neus formed
by in vitro stimulation with ADP, thrombin, or U46619 were
significantly increased one month after the operation but
reduced compared to baseline at three months. Agonist stimu-
lated P-Lyms were increased at one month and remained
increased at three months after ADP stimulation.
Correlations
There were several significant correlations at one and
three months between agonist stimulated levels of platelet
P-selectin expression and the corresponding agonist stimulated
PLA formation in vitro (Supplementary Table III).
Discussion
In the present study, we found mildly increased platelet respon-
siveness to agonist stimulation using whole blood flow cytometry
up to three months after elective CABG despite ASA use.
Circulating PLAs of all subtypes (platelet-conjugated monocytes,
neutrophils, and lymphocytes) were elevated one month after sur-
gery, and agonist stimulated PLA formation ex vivo was also
enhanced at this time point. Agonist stimulated P-Mon and P-Neu
formation was reduced at three months compared to baseline
whereas P-Lym formation was not. There was no pattern indicating
selectivity for any signaling pathway as platelet and PLA respon-
siveness was elevated with stimulation by ADP, thrombin, and a
thromboxane analog.We have previously shown that CABG causes
early (within one week) activation of circulating platelets and
leukocytes, increased numbers of circulating PLAs, and marked
activation of coagulation and inflammatory responses [11]. We
presently show that platelet and PLA responses are protracted
and in some cases not normalized even after three months.
Only patients with stable coronary artery disease who underwent
elective CABGwere included in this study as patients treated for acute
coronary syndromes require dual antiplatelet treatment after the
operation [23]. ASA was not discontinued before the operation, as
the associated bleeding risk is small and withdrawal would leave the
patient unprotected against acute ischemic events [21,24,25]. Minor
bleeding that in some cases might have been associated with ASA
treatment was reported by 15% of the patients during the follow-up.
Flow cytometric assays under static conditions are independent of
thromboxane formation due to platelet aggregation, and can be used to
investigate platelets regardless of ASA therapy [17–19]. In agreement
with this, we found no differences between groups treated with
different ASA dosages and could pool all patients.
CABG performed with the aid of cardiopulmonary bypass
caused an early drop in hemoglobin levels reflecting blood loss
and hemodilution. Leukocyte counts were the highest 4–6 days
after the operation reflecting inflammatory responses to cardio-
pulmonary bypass [9]. These changes were normalized three
months after the operation. Platelet counts were markedly ele-
vated one month after the operation but mean platelet volume that
reflects platelet turnover and platelet reactivity (large, newly
formed platelets being more reactive) did not change [26].
The postoperative responses to CABG with cardiopulmonary
bypass were more pronounced for PLAs than for single platelets.
It is of interest that P-Mons may be a more sensitive marker for
platelet activation in vivo than P-selectin expression on single
platelets [27] presumably since circulating platelets shed the
exposed P-selectin in vivo [28]. This may explain why the
P-selectin expression of unstimulated (circulating) platelets did
Platelet P-selectin expression



























Figure 2. Mean percentages with 95% confidence limits for platelet P-selectin positive cells in the platelet population in 54 patients before and after
CABG. Unstimulated basal levels and levels after agonist stimulation by adenosine diphosphate (ADP), thrombin, and the thromboxane A2 analog
U46619 are shown. Dashed columns indicate results 4–6 days after surgery, shaded columns at one month, and black columns at three months.
**p < 0.01 and ***p < 0.001 for difference between postoperative and preoperative levels are indicated.
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not change, whereas circulating P-Mons were increased at
one month. Increased platelet reactivity to agonist stimulation
ex vivo was found up to three months after surgery, and larger
responses were detected among PLAs than among single plate-
lets in the present study. Of interest is that agonist stimulated
platelet P-selectin expression correlated with the corresponding
formation of PLAs at one and three months, as shown in
Supplementary Table III. Thus, platelet sensitization appears to
be of importance for the increased reactivity of PLAs after
CABG surgery.
Platelets that are adhered to the endothelium and platelets
binding to leukocytes are involved in the recruitment of leuko-
cytes to the vessel wall and the initiation of vascular inflamma-
tion and atherosclerosis [4,6–8,29]. Binding via P-selectin
glycoprotein ligand-1 is crucial in the interaction between plate-
lets and the microvascular endothelium as well as in interactions
with leukocytes and the formation of PLAs [29,30]. Neutrophils
can be activated by high mobility group box 1 protein expressed
in platelets, and neutrophil extracellular traps play a key role in
interaction with platelets [31]. Platelet binding to monocytes
increases their adhesiveness and transendothelial migration, and
platelet binding to neutrophils promotes transmigration and their
recruitment to inflammatory sites [4,29,30]. Recent work has
shown a crucial importance of platelets in guiding neutrophils
and inflammatory monocytes to their exit points in the micro-
vasculature [32]. The present data showing increased circulating
P-Mons and P-Neus, as well as increased responses to agonist
stimulation ex vivo one month after the CABG operation, may be
interpreted as reflecting inflammatory and prothrombotic chal-
lenges to the vasculature. The P-Mon and P-Neu responses were
lower than before the operation after three months, indicating
wound healing and subsiding inflammation, whereas signs of
mildly increased platelet reactivity persisted. Clearance of acti-
vated platelets and neutrophils from the circulation and the asso-
ciated decrease in platelet–leukocyte aggregates may have
contributed to this finding [28,33]. Platelets participate in the
regulation of CD4 positive T-cells with implications for immune
responses and vascular inflammation [8,34]. Our findings of
increased platelet binding to lymphocytes and increased agonist
stimulated formation of P-Lyms one month after the CABG
procedure are of interest in this context.
Activated platelets and formation of PLAs may increase the
risk of thrombosis after CABG. The present data support the need
for efficient antiplatelet therapy during the first three months after
Platelet monocyte aggregates (%)
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Figure 3. Mean percentages with 95% confidence limits of (a) CD14 positive platelet–monocyte aggregates (P-Mon), (b) platelet–neutrophil aggregates
(P-neu), and (c) platelet–lymphocyte aggregates (P-lym) in 54 patients before and after CABG. Unstimulated levels and levels after agonist stimulation
by ADP, thrombin, and the thromboxane A2 analog U46619 are shown. Dashed columns indicate results 4–6 days after surgery, shaded columns at one
month, and black columns at three months. **p < 0.01 and ***p < 0.001 for difference between postoperative and preoperative levels are indicated.
DOI: https://doi.org/10.1080/09537104.2018.1542122 Platelet function after CABG 979
the operation. Dual antiplatelet therapy may be an option for a
limited period of time also among stable patients undergoing
elective CABG.
Limitations
We were not able to include all screened patients as we required a
follow-up examination of surviving patients three months after the
operation, and good-quality blood samples for flow cytometry with
minimal in vitro artefacts at all time points. The patients were treated
with different low doses of ASA after the operation [16] but we do
not believe this has confounded our findings since flow cytometry of
single platelets or PLAs is not influenced by the thromboxane path-
way of platelet activation [17–19] and the flow cytometric data
reported here did not vary between the ASA treatment groups.
Conclusions
We conclude that elective CABG in ASA-treated patients with
stable coronary artery disease evoked mild signs of platelet acti-
vation up to three months after the operation. Increased platelet–
leukocyte interactions that may facilitate vascular inflammation
and thrombosis were found especially one month after the opera-
tion. Our findings support further studies of the clinical implica-
tions of protracted platelet activation after CABG.
Supplementary data
Supplementary data for this article can be accessed here.
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